share_log

BRIEF-Regenxbio Announces Additional Positive Long-Term And Interim Phase I/Iia Trial Update For Rgx-314 For The Treatment Of Wet AMD

Reuters ·  Apr 22, 2020 18:33

April 22 (Reuters) - Regenxbio Inc RGNX.O :

* REGENXBIO ANNOUNCES ADDITIONAL POSITIVE LONG-TERM AND INTERIM PHASE I/IIA TRIAL UPDATE FOR RGX-314 FOR THE TREATMENT OF WET AMD

* REGENXBIO INC - RGX-314 CONTINUES TO BE WELL-TOLERATED AT ALL DOSE LEVELS

* REGENXBIO INC - ON TRACK TO PROVIDE ONE-YEAR DATA FROM COHORTS 4 & 5 IN MID-2020 AND INITIATE RGX-314 SUBRETINAL DELIVERY PIVOTAL PROGRAM IN 2H 2020

* REGENXBIO INC - LONG-TERM, DURABLE TREATMENT EFFECT DEMONSTRATED OVER TWO YEARS IN COHORT 3 IN WET AMD TRIAL

* REGENXBIO INC - IN WET AMD TRIAL, 50% OF PATIENTS REMAIN ANTI-VEGF INJECTION-FREE OVER TWO YEARS

* REGENXBIO INC - IN WET AMD TRIAL, 67% OF PATIENTS ARE ANTI-VEGF INJECTION-FREE FROM NINE MONTHS TO TWO YEARS

Source text for Eikon: Further company coverage:

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment